InspireMD Inc. (NSPR): Price and Financial Metrics

InspireMD Inc. (NSPR): $2.21

0.04 (+1.84%)

POWR Rating

Component Grades














  • NSPR scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.64% of US stocks.
  • The strongest trend for NSPR is in Quality, which has been heading down over the past 75 days.
  • NSPR ranks lowest in Quality; there it ranks in the 1st percentile.

NSPR Stock Summary

  • NSPR has a market capitalization of $26,631,805 -- more than approximately only 4.94% of US stocks.
  • For NSPR, its debt to operating expenses ratio is greater than that reported by merely 9.92% of US equities we're observing.
  • InspireMD Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -131.55%, greater than the shareholder yield of only 2.81% of stocks in our set.
  • Stocks that are quantitatively similar to NSPR, based on their financial statements, market capitalization, and price volatility, are VYNE, TUFN, ERII, LKCO, and EGAN.
  • NSPR's SEC filings can be seen here. And to visit InspireMD Inc's official web site, go to

NSPR Valuation Summary

  • NSPR's price/sales ratio is 11.3; this is 197.37% higher than that of the median Healthcare stock.
  • NSPR's price/sales ratio has moved NA NA over the prior 126 months.
  • Over the past 126 months, NSPR's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for NSPR.

Stock Date P/S P/B P/E EV/EBIT
NSPR 2021-08-31 11.3 0.9 -2.8 0.4
NSPR 2021-08-30 11.2 0.9 -2.8 0.4
NSPR 2021-08-27 11.3 0.9 -2.8 0.4
NSPR 2021-08-26 9.8 0.8 -2.4 0.7
NSPR 2021-08-25 10.2 0.8 -2.5 0.6
NSPR 2021-08-24 10.2 0.8 -2.5 0.6

NSPR Growth Metrics

    Its 3 year revenue growth rate is now at 25.58%.
  • Its 3 year net income to common stockholders growth rate is now at 34.42%.
  • The year over year revenue growth rate now stands at -43.39%.
Over the past 15 months, NSPR's revenue has gone up $1,155,000.

The table below shows NSPR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 4.495 -13.21 -14.918
2021-09-30 3.273 -12.509 -14.674
2021-06-30 3.182 -11.413 -12.836
2021-03-31 2.457 -10.368 -11.809
2020-12-31 2.485 -9.081 -10.544
2020-09-30 3.34 -8.449 -9.248

NSPR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NSPR has a Quality Grade of F, ranking ahead of 2.38% of graded US stocks.
  • NSPR's asset turnover comes in at 0.099 -- ranking 153rd of 186 Medical Equipment stocks.
  • NEPH, PODD, and COO are the stocks whose asset turnover ratios are most correlated with NSPR.

The table below shows NSPR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.099 0.087 -4.886
2021-03-31 0.099 -0.043 -5.025
2020-12-31 0.170 0.033 -4.722
2020-09-30 0.264 0.219 -4.531
2020-09-30 0.264 0.219 -4.531
2020-06-30 0.283 0.170 -4.563

NSPR Price Target

For more insight on analysts targets of NSPR, see our NSPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.5 (Moderate Buy)

NSPR Stock Price Chart Interactive Chart >

Price chart for NSPR

NSPR Price/Volume Stats

Current price $2.21 52-week high $6.82
Prev. close $2.17 52-week low $1.91
Day low $2.18 Volume 9,299
Day high $2.32 Avg. volume 32,017
50-day MA $2.74 Dividend yield N/A
200-day MA $3.36 Market Cap 18.39M

InspireMD Inc. (NSPR) Company Bio

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.

NSPR Latest News Stream

Event/Time News Detail
Loading, please wait...

NSPR Latest Social Stream

Loading social stream, please wait...

View Full NSPR Social Stream

Latest NSPR News From Around the Web

Below are the latest news stories about InspireMD Inc that investors may wish to consider to help them evaluate NSPR as an investment opportunity.

InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update

-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- TEL AVIV, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report fourth quarter and full year 2021 financial results on Tuesday, March 8, 2022, before the market opens. Management will host a conference call and webcast with the

Yahoo | February 22, 2022

InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor

Dr. Siddiqui is recognized for his extensive experience in Microsurgical, Radiosurgical and Endovascular Techniques for the Comprehensive Management of Vascular DiseaseTEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced the appointment of Adnan Siddiqui, MD, PhD, FAANS, FACS, FAHA to the Company’s S

Yahoo | February 15, 2022

InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

- Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 -TEL AVIV, Israel, Jan. 27, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that Marvin Slosman, Chief Executive Officer, is scheduled to present at the IAGS’ Biennial Scientific Meeting being held from January 31 – February 3, 2022 in Punta Cana, Dominica

Yahoo | January 27, 2022

InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

Live Case will be Broadcasted Today at 11:00am ETTEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that a live case demonstration featuring CGuard™ EPS will be broadcasted at the International Symposium on Endovascular Therapy (ISET) 2022 Conference by Dr. Chris Metzger, Chair of Clinical Research at Ballad Health on Tue

Yahoo | January 18, 2022

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 22, 2021

Read More 'NSPR' Stories Here

NSPR Price Returns

1-mo N/A
3-mo -15.00%
6-mo -37.75%
1-year -51.85%
3-year -95.49%
5-year -99.98%
YTD -26.82%
2021 -40.94%
2020 -68.44%
2019 -86.42%
2018 -96.45%
2017 -94.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9084 seconds.